
Keywords: ECM; Extracellular matrix; TIMP-1; tissue inhibitor of matrix metalloproteinases-1; HA; hyaluronic acid; IPF; idiopathic pulmonary fibrosis; FDA; Food and Drug Administration; bFGF; basic fibroblast growth factor; IFN-γ; interferon-γ; IL; interleukin; P